• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure misses Q4 EPS by a penny, tops sales estimates

February 22, 2018 By Sarah Faulkner

NovocureShares in Novocure (NSDQ:NVCR) rose slightly today in premarket activity after the medical device maker met sales expectations, but missed earnings estimates on Wall Street with its fourth quarter and full-year financial results.

The St. Helier, N.J.-based company reeled in losses this quarter, posting -$10.9 million on sales of $53.7 million for the 3 months ended Dec. 31, for sales growth of 78% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -12¢, a penny behind consensus on The Street, where analysts were looking for sales of $53.6 million.

For the full year, Novocure posted a net loss of -$61.7 million on sales of $177 million, up 114% from the previous year.

“With more than 1,800 patients on therapy at year-end, the fourth quarter of 2017 was our 12th consecutive quarter of active patient growth since the initial presentation of our EF-14 Phase III pivotal clinical trial data,” CEO Asaf Danziger said in prepared remarks. “I am proud of the progress we made in 2017.”

“We believe Novocure has significant potential to both grow our GBM business and to expand into additional solid tumor indications,” chairman William Doyle added. “We now have more than 1,100 centers certified across three regions of the world, reflecting our growing global commercial reach, and we believe there are far more patients who could benefit from treatment with Optune than are currently on therapy. With three ongoing Phase III pivotal trials and data expected from a large Phase II pilot trial in mesothelioma in 2018, we believe we are still at the beginning of our journey.”

NVCR shares were trading at $21.75 apiece today in premarket activity, up 0.9%.

Novocure’s system, Optune, delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication.

In a pivotal Phase III trial comparing Optune and temozolomide to temozolomide alone, the combination therapy significantly extended overall survival for patients with newly diagnosed glioblastoma.

Data from the trial also showed that patients in the Optune group maintained their quality of life for a longer period of time compared to patients in the temozolomide group.

In December, the Japanese government agreed to reimburse for Novocure’s Optune as a therapy for newly-diagnosed GBM.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: NovoCure

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS